Multiple sclerosis（MS）is a central nervous system autoimmune disease which mostly involve young patients. Diagnosis of MS in our country is mainly based on 2010 revisions to the Mc Donald criteria. Taken into consideration of the relatively high morbidity of neuromyelitis optica spectrum disorders（NMOSD） in China

the differential diagnosis of MS and NMOSD is important. The main treatment strategy in acute phase is high-dose glucocorticoid

while the main therapy in remission phase is immunosuppressive drugs in our country due to lack of disease modifying medication. The difference between our country and developed countries in Europe and America in the diagnosis and treatment of MS is still exist. Developing large and multi-center MS case database

improving the ability of early diagnosis and treatment of MS in primary hospital

promoting the availability of disease modifying medication on Chinese market

as well as promoting new drug research and development

are all effective ways to improve the situation.